Most Recent
APRA has been accused of harbouring an “unhinged hatred” for former IOOF managing director Chris Kelaher by his counsel, who was objecting to internal APRA documents he claims were disparaging of the wealth management company and its executives.
The former CEO and director of biotech company Sirtex Medical, Gilman Wong, is facing a maximum ten years in prison after pleading guilty to insider trading.
The prudential regulator has opened the first day of its case against IOOF directors and entities by claiming the wealth manager's liability is “plain as a pike staff”, as IOOF contends the regulator’s case is “artificial and theoretical” and “overly simplistic”.
Sirtex Medical has reached a mid-trial agreement to resolve a shareholder class action that centred on the biotech company's sales forecasts of its radiation treatment.
Former executives of wealth manager IOOF facing disqualification proceedings by the Australian Prudential Regulation Authority have criticised the prudential regulator for a late and extensive discovery request, saying it could "imperil" the July trial date.
Sirtex has been ordered to turn over information related to a possible acquisition to law firm Maurice Blackburn, which is leading a shareholder class action against the life sciences company.
Two rulings Friday keeping alive the common fund order are a ringing endorsement by the courts of the important role that litigation funders play in class actions, experts say, and have paved the way for more funded post-Hayne consumer litigation against banks and other financial services firms this year.
Common fund orders in class actions are legal and not unconstitutional, six judges found Friday after a history-making joint sitting of two appeals courts.